- Home
- ANGO vs NYXH Comparison
ANGO vs NYXH Comparison
Compare ANGO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- NYXH
- Stock Information
- Founded
- ANGO 1988
- NYXH 2009
- Country
- ANGO United States
- NYXH Belgium
- Employees
- ANGO N/A
- NYXH N/A
- Industry
- ANGO Medical/Dental Instruments
- NYXH Medical/Dental Instruments
- Sector
- ANGO Health Care
- NYXH Health Care
- Exchange
- ANGO Nasdaq
- NYXH Nasdaq
- Market Cap
- ANGO 401.4M
- NYXH 394.1M
- IPO Year
- ANGO 2004
- NYXH 2021
- Fundamental
- Price
- ANGO $9.39
- NYXH $6.90
- Analyst Decision
- ANGO Strong Buy
- NYXH Strong Buy
- Analyst Count
- ANGO 3
- NYXH 4
- Target Price
- ANGO $13.00
- NYXH $14.75
- AVG Volume (30 Days)
- ANGO 479.1K
- NYXH 81.9K
- Earning Date
- ANGO 04-02-2025
- NYXH 03-13-2025
- Dividend Yield
- ANGO N/A
- NYXH N/A
- EPS Growth
- ANGO N/A
- NYXH N/A
- EPS
- ANGO N/A
- NYXH N/A
- Revenue
- ANGO $286,498,000.00
- NYXH $4,680,609.00
- Revenue This Year
- ANGO N/A
- NYXH $504.18
- Revenue Next Year
- ANGO $6.63
- NYXH $149.52
- P/E Ratio
- ANGO N/A
- NYXH N/A
- Revenue Growth
- ANGO N/A
- NYXH 3.98
- 52 Week Low
- ANGO $5.47
- NYXH $6.76
- 52 Week High
- ANGO $13.50
- NYXH $13.50
- Technical
- Relative Strength Index (RSI)
- ANGO 43.99
- NYXH 23.12
- Support Level
- ANGO $9.34
- NYXH $10.26
- Resistance Level
- ANGO $10.29
- NYXH $11.87
- Average True Range (ATR)
- ANGO 0.39
- NYXH 0.77
- MACD
- ANGO 0.06
- NYXH -0.45
- Stochastic Oscillator
- ANGO 32.84
- NYXH 1.19
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.